NCX 470 is currently licensed to Ocumension Therapeutics for China, Korea, and Southeast Asia. According to Nicox, projected ...
Malar edema, the collection of fluid below the infraorbital rim and over the malar eminence, presents a unique challenge to ...
“TED is 5 times more prevalent in women, and because of that, men are often overlooked for the diagnosis,” Nijm said. The ...
They explore how rapid symptom relief affects satisfaction, outline current unmet needs in DED treatment, and share guidance ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for ...
Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...
Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective ...
"Lubricating drops" is proposed as a more accurate term, reflecting their primary function of providing lubrication and ...
Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...
Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback